Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | SCN4A | P35499 | 2/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7253237 | 0.80 | TACR1 (0.42) | SIGMAR1TACR1 | |
| SCHEMBL7251051 | 0.78 | APP (0.43) | — | |
| Trifluoroacetic Acid SCHEMBL7251980 | 0.78 | CPB2 (0.39) | DRD2DRD4SIGMAR1TACR1PREP | |
| SCHEMBL7248694 | 0.77 | NOTCH1 (0.43) | — | |
| SCHEMBL3616171 | 0.75 | HDAC1 (0.50) | FPR2DRD2DRD4SIGMAR1SCN4A | |
| SCHEMBL19614234 | 0.68 | DRD4 (0.70) | L3MBTL1DRD2DRD4SIGMAR1 | |
| SCHEMBL20183285 | 0.68 | DRD4 (0.70) | L3MBTL1DRD2DRD4SIGMAR1 | |
| SCHEMBL17961749 | 0.68 | DRD4 (0.70) | L3MBTL1DRD2DRD4SIGMAR1 | |
| SCHEMBL25154608 | 0.67 | DRD4 (0.46) | DRD4SIGMAR1 | |
| SCHEMBL25154267 | 0.67 | DRD4 (0.46) | DRD4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6525044-B2 | Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-25 | — | — | US | disclosed |
| EP-1261610-A2 | SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020055501-A1 | Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-09 | — | — | US | disclosed |
| WO-2001060826-A2 | SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055501-A1 | Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production | APP, APH1A, APH1B | FPR2 3577/4885L3MBTL1 3027/4885DRD2 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.